Advances in Management of Gastrointestinal Stromal Tumors with Secondary Resistance to Imatinib
10.3969/j.issn.1008-7125.2015.06.009
- VernacularTitle:胃肠道间质瘤伊马替尼继发耐药治疗的研究进展
- Author:
Jia ZHENG
;
Qingxiang YU
;
Li WANG
;
Bangmao WANG
- Publication Type:Journal Article
- Keywords:
Gastrointestinal Stromal Tumors;
Imatinib;
Secondary Resistance;
Molecular Targeted Therapy;
Drug Therapy,Combination
- From:
Chinese Journal of Gastroenterology
2015;(6):373-376
- CountryChina
- Language:Chinese
-
Abstract:
The use of tyrosine kinase inhibitor imatinib in treatment of gastrointestinal stromal tumors(GISTs)has achieved a dramatic therapeutic efficacy. However,secondary imatinib resistance emerged as a clinical problem needs to be solved urgently. The underlying mechanisms of GISTs secondary resistance to imatinib may be related with secondary mutations of KIT/ PDGFRA genes,loss of PTEN gene and induction of cellular quiescence. This resulted in the adoption of new therapeutic strategies such as novel tyrosine kinase inhibitors,combined use of imatinib with downstream signaling inhibitors,KIT/ PDGFRA independent targeted inhibitors such as KIT chaperone inhibitors and aurora kinase inhibitors,as well as inducing apoptosis in quiescent GIST cells. In this article,the above-mentioned issues were summarized.
